| (+)-Epiloliolide |
|
|
|
|
95.0% |
| (+)-Magnoflorine |
|
|
|
|
|
| (6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-CoA |
|
|
|
|
|
| (E/Z)-Necrosulfonamide |
|
|
|
|
98.03% |
| (R)-Colchicine |
|
|
|
|
|
| (rac)-NDT-19795 |
|
|
|
|
99.34% |
| (S)-NDT-19795 |
|
|
|
|
|
| (±)11(12)-EET |
|
|
|
|
98.3% |
| (±)11(12)-EET-d11 |
|
|
|
|
|
| 2-Guanidinobezimidazole |
|
|
|
|
95.74% |
| 3-Et-3TC |
|
|
|
|
|
| Moronic acid |
|
|
|
|
98.6% |
| 5-O-Methylvisammioside |
|
|
|
|
99.90% |
| 7-Oxogedunin |
|
|
|
|
|
| 7DG |
|
|
|
|
98% |
| ABT-546 |
|
|
|
|
|
| AChE/BChE-IN-23 |
|
|
|
|
|
| ADS032 |
|
|
|
|
99.89% |
| AJ2-30 |
|
|
|
|
99.72% |
| Altechromone A |
|
|
|
|
|
| Aluminum phosphate adjuvant |
|
|
|
|
|
| Amelenodor |
|
|
|
|
|
| Aminoadipic acid |
|
|
|
|
99.94% |
| AMS-17 |
|
|
|
|
98.09% |
| Anemoside A3-methyl 6-aminohexanoate |
|
|
|
|
98.62% |
| Antcin A |
|
|
|
|
99.71% |
| Anti-inflammatory agent 114 |
|
|
|
|
|
| Anti-neuroinflammation agent 1 |
|
|
|
|
|
| Articaine |
|
|
|
|
|
| Articaine (Standard) |
|
|
|
|
|
| ATP disodium salt, 100 mM Solution, PCR Grade |
|
|
|
|
|
| AZD4144 |
|
|
|
|
99.67% |
| BAL-0028 |
|
|
|
|
99.86% |
| BAL-1516 |
|
|
|
|
|
| BD-AcAc2 |
|
|
|
|
|
| Benzylurea |
|
|
|
|
99.94% |
| BLT1-IN-1 |
|
|
|
|
|
| BMS-986299 |
|
|
|
|
99.96% |
| Britannin |
|
|
|
|
99.93% |
| BuChE-IN-20 |
|
|
|
|
|
| C12-iE-DAP |
|
|
|
|
|
| C12-iE-DAP hydrochloride |
|
|
|
|
96.59% |
| C14-Tri-LAN-Gly |
|
|
|
|
|
| CAII-IN-11 |
|
|
|
|
|
| CAII-IN-15 |
|
|
|
|
|
| Callicarboric acid A |
|
|
|
|
|
| Candidalysin |
|
|
|
|
99.81% |
| Cichoriin |
|
|
|
|
99.9% |
| Citraconic acid |
|
|
|
|
99.08% |
| Citraconic acid (Standard) |
|
|
|
|
98% |
| Convulxin |
|
|
|
|
|
| CORM-3 |
|
|
|
|
97.5% |
| COX-2/NLRP3-IN-1 |
|
|
|
|
|
| CP-424174 |
|
|
|
|
98.69% |
| CSC-6 |
|
|
|
|
|
| CSLP43 |
|
|
|
|
|
| CVN293 |
|
|
|
|
99.91% |
| CXCR2-IN-3 |
|
|
|
|
|
| CY-09 |
|
|
|
|
99.58% |
| D359-0396 |
|
|
|
|
99.98% |
| Dapansutrile |
|
|
|
|
99.92% |
| Daphnoretin |
|
|
|
|
99.83% |
| Defensin HNP-1 human |
|
|
|
|
98.12% |
| Defensin HNP-1 human TFA |
|
|
|
|
99.08% |
| Dehydrodiisoeugenol-d4 |
|
|
|
|
|
| DPO-1 |
|
|
|
|
98.39% |
| DPP4-In hydrochloride |
|
|
|
|
|
| Drofenine |
|
|
|
|
|
| EMD638683 |
|
|
|
|
99.94% |
| Emlenoflast |
|
|
|
|
99.30% |
| Emlenoflast sodium |
|
|
|
|
98.31% |
| Fc 11a-2 |
|
|
|
|
99.75% |
| FK-565 |
|
|
|
|
99.88% |
| Forsythoside I |
|
|
|
|
99.94% |
| Garcinoic acid |
|
|
|
|
|
| GDC-2394 |
|
|
|
|
99.87% |
| GDC-2394 sodium |
|
|
|
|
|
| GFAP/NF-κB/APOE/NLRP3-IN-1 |
|
|
|
|
|
| GSK223 |
|
|
|
|
|
| GSK717 |
|
|
|
|
99.93% |
| Hck-IN-3 |
|
|
|
|
|
| HDAC3 degrader-1 |
|
|
|
|
|
| HDAC3 degrader-2 |
|
|
|
|
|
| HDAC6-IN-54 |
|
|
|
|
|
| HMGB1-IN-1 |
|
|
|
|
98.40% |
| HNW005 |
|
|
|
|
|
| Human NLRP3 mRNA |
|
|
|
|
|
| Icariside I |
|
|
|
|
98.76% |
| Icariside I (Standard) |
|
|
|
|
98% |
| iE-DAP |
|
|
|
|
|
| iE-DAP dihydrochloride |
|
|
|
|
|
| IIIM-1266 |
|
|
|
|
|
| IIIM-1270 |
|
|
|
|
98.78% |
| Inclisiran sodium scrambled negative control |
|
|
|
|
|
| INF 195 |
|
|
|
|
99.58% |
| INF200 |
|
|
|
|
|
| INF39 |
|
|
|
|
99.75% |
| INF4E |
|
|
|
|
99.38% |
| Isoandrographolide |
|
|
|
|
98.34% |
| JC-171 |
|
|
|
|
98.06% |
| JC124 |
|
|
|
|
99.72% |
| JC2-11 |
|
|
|
|
98.03% |
| JNJ-79883960 |
|
|
|
|
|
| JNUTS013 |
|
|
|
|
|
| JT001 |
|
|
|
|
|
| JT001 sodium |
|
|
|
|
98.39% |
| JT002 |
|
|
|
|
99.54% |
| Kanglexin |
|
|
|
|
99.65% |
| L6H21 |
|
|
|
|
99.19% |
| Ligusticum cycloprolactam |
|
|
|
|
|
| LYRM03 |
|
|
|
|
|
| M-TriDAP |
|
|
|
|
98.0% |
| M-TriDAP TFA |
|
|
|
|
|
| M464 |
|
|
|
|
99.58% |
| Maackiain |
|
|
|
|
99.83% |
| Macarangin |
|
|
|
|
|
| Magnesium isoglycyrrhizinate hydrate |
|
|
|
|
99.81% |
| Maresin 2 |
|
|
|
|
97.2% |
| MBL-1 |
|
|
|
|
|
| MC-ND-18 |
|
|
|
|
|
| MC1 |
|
|
|
|
|
| MCC950 |
|
|
|
|
99.78% |
| MCC950 sodium |
|
|
|
|
99.75% |
| Mifamurtide sodium hydrate |
|
|
|
|
|
| Mito-TEMPO |
|
|
|
|
99.19% |
| MitoTEMPO hydrate |
|
|
|
|
98.03% |
| ML345 |
|
|
|
|
99.37% |
| MNP2 |
|
|
|
|
|
| MNS |
|
|
|
|
|
| Mouse Serum Albumin |
|
|
|
|
95% |
| MR2938 |
|
|
|
|
|
| MS-II-124 |
|
|
|
|
99.66% |
| Multitarget AD-IN-6 |
|
|
|
|
|
| Muramyl dipeptide |
|
|
|
|
99.07% |
| Muramyl dipeptide-d3 |
|
|
|
|
|
| N4-Acetylcytidine |
|
|
|
|
99.65% |
| N4-Acetylcytidine-13C5 |
|
|
|
|
95.92% |
| Nangibotide |
|
|
|
|
98.53% |
| Nangibotide TFA |
|
|
|
|
99.36% |
| NBC19 |
|
|
|
|
99.22% |
| NDT-19795 |
|
|
|
|
99.16% |
| NDT-30805 |
|
|
|
|
|
| Necrosulfonamide |
|
|
|
|
98.61% |
| Necrosulfonamide-d4 |
|
|
|
|
99.65% |
| NEK7 degrader-1 |
|
|
|
|
99.94% |
| NEK7 degrader-2 |
|
|
|
|
|
| NEK7 degrader-3 |
|
|
|
|
|
| NEK7-IN-2 |
|
|
|
|
|
| Neral |
|
|
|
|
97.87% |
| Neuroprotective agent 8 |
|
|
|
|
|
| NIC-0102 |
|
|
|
|
98.79% |
| NIC-12 |
|
|
|
|
|
| NK7-902 diTFA |
|
|
|
|
99.88% |
| NLRP3 agonist 1 |
|
|
|
|
99.47% |
| NLRP3 agonist 2 |
|
|
|
|
|
| NLRP3 antagonist 1 |
|
|
|
|
98.86% |
| NLRP3 modulator 1 |
|
|
|
|
|
| NLRP3 modulator 7 |
|
|
|
|
|
| NLRP3-IN-11 |
|
|
|
|
98.79% |
| NLRP3-IN-12 |
|
|
|
|
|
| NLRP3-IN-13 |
|
|
|
|
98.03% |
| NLRP3-IN-14 |
|
|
|
|
|
| NLRP3-IN-15 |
|
|
|
|
|
| NLRP3-IN-16 |
|
|
|
|
|
| NLRP3-IN-17 |
|
|
|
|
99.02% |
| NLRP3-IN-18 |
|
|
|
|
98.06% |
| NLRP3-IN-2 |
|
|
|
|
98.0% |
| NLRP3-IN-20 |
|
|
|
|
|
| NLRP3-IN-21 |
|
|
|
|
98.97% |
| NLRP3-IN-22 |
|
|
|
|
|
| NLRP3-IN-23 |
|
|
|
|
|
| NLRP3-IN-25 |
|
|
|
|
99.78% |
| NLRP3-IN-26 |
|
|
|
|
|
| NLRP3-IN-27 |
|
|
|
|
|
| NLRP3-IN-28 |
|
|
|
|
|
| NLRP3-IN-29 |
|
|
|
|
|
| NLRP3-IN-30 |
|
|
|
|
|
| NLRP3-IN-31 |
|
|
|
|
|
| NLRP3-IN-32 |
|
|
|
|
|
| NLRP3-IN-34 |
|
|
|
|
|
| NLRP3-IN-35 |
|
|
|
|
|
| NLRP3-IN-36 |
|
|
|
|
|
| NLRP3-IN-37 |
|
|
|
|
|
| NLRP3-IN-38 |
|
|
|
|
|
| NLRP3-IN-4 |
|
|
|
|
|
| NLRP3-IN-40 |
|
|
|
|
|
| NLRP3-IN-41 |
|
|
|
|
|
| NLRP3-IN-42 |
|
|
|
|
|
| NLRP3-IN-43 |
|
|
|
|
|
| NLRP3-IN-44 |
|
|
|
|
|
| NLRP3-IN-45 |
|
|
|
|
|
| NLRP3-IN-46 |
|
|
|
|
|
| NLRP3-IN-48 |
|
|
|
|
|
| NLRP3-IN-49 |
|
|
|
|
|
| NLRP3-IN-50 |
|
|
|
|
|
| NLRP3-IN-52 |
|
|
|
|
|
| NLRP3-IN-53 |
|
|
|
|
|
| NLRP3-IN-54 |
|
|
|
|
|
| NLRP3-IN-55 |
|
|
|
|
|
| NLRP3-IN-56 |
|
|
|
|
|
| NLRP3-IN-57 |
|
|
|
|
|
| NLRP3-IN-58 |
|
|
|
|
|
| NLRP3-IN-6 |
|
|
|
|
|
| NLRP3-IN-60 |
|
|
|
|
|
| NLRP3-IN-61 |
|
|
|
|
|
| NLRP3-IN-62 |
|
|
|
|
|
| NLRP3-IN-63 |
|
|
|
|
|
| NLRP3-IN-64 |
|
|
|
|
|
| NLRP3-IN-65 |
|
|
|
|
|
| NLRP3-IN-66 |
|
|
|
|
|
| NLRP3-IN-67 |
|
|
|
|
|
| NLRP3-IN-68 |
|
|
|
|
|
| NLRP3-IN-69 |
|
|
|
|
|
| NLRP3-IN-7 |
|
|
|
|
|
| NLRP3-IN-70 |
|
|
|
|
|
| NLRP3-IN-71 |
|
|
|
|
|
| NLRP3-IN-72 |
|
|
|
|
|
| NLRP3-IN-73 |
|
|
|
|
|
| NLRP3-IN-74 |
|
|
|
|
|
| NLRP3-IN-75 |
|
|
|
|
|
| NLRP3-IN-76 |
|
|
|
|
|
| NLRP3-IN-77 |
|
|
|
|
|
| NLRP3-IN-79 |
|
|
|
|
99.10% |
| NLRP3-IN-8 |
|
|
|
|
|
| NLRP3-IN-80 |
|
|
|
|
99.43% |
| NLRP3-IN-81 |
|
|
|
|
|
| NLRP3-IN-82 |
|
|
|
|
|
| NLRP3-IN-83 |
|
|
|
|
|
| NLRP3-IN-84 |
|
|
|
|
|
| NLRP3-IN-85 |
|
|
|
|
|
| NLRP3-IN-86 |
|
|
|
|
|
| NLRP3-IN-87 |
|
|
|
|
|
| NLRP3-IN-88 |
|
|
|
|
|
| NLRP3-IN-89 |
|
|
|
|
|
| NLRP3-IN-9 |
|
|
|
|
|
| NLRP3-IN-90 |
|
|
|
|
|
| NLRP3-IN-91 |
|
|
|
|
|
| NLRP3-IN-94 |
|
|
|
|
99.93% |
| NLRP3-IN-NBC6 |
|
|
|
|
|
| NLRP3/AIM2-IN-1 |
|
|
|
|
|
| NLRP3/AIM2-IN-3 |
|
|
|
|
98.23% |
| NLRP3/URAT1-IN-1 |
|
|
|
|
|
| NOD-IN-1 |
|
|
|
|
99.48% |
| NOD1 antagonist-1 |
|
|
|
|
|
| NOD1 antagonist-2 |
|
|
|
|
|
| NOD1 Human Pre-designed siRNA Set A |
|
|
|
|
|
| Nod1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| NOD1-IN-1 |
|
|
|
|
|
| NOD1-RIPK2-IN-1 |
|
|
|
|
|
| NOD1/2 antagonist-1 |
|
|
|
|
|
| NOD1/2 antagonist-2 |
|
|
|
|
|
| NOD1/2-IN-1 |
|
|
|
|
|
| NOD2 agonist 1 |
|
|
|
|
|
| NOD2 agonist 2 |
|
|
|
|
|
| NOD2 agonist 3 |
|
|
|
|
|
| NOD2 agonist 4 |
|
|
|
|
|
| NOD2 antagonist 1 |
|
|
|
|
99.57% |
| NOD2 Human Pre-designed siRNA Set A |
|
|
|
|
|
| NOD2/TLR4 agonist-1 |
|
|
|
|
|
| Nodinitib-1 |
|
|
|
|
99.94% |
| NP-1815-PX |
|
|
|
|
|
| NP-1815-PX sodium |
|
|
|
|
99.51% |
| NP3-146 |
|
|
|
|
|
| NP3-146 sodium |
|
|
|
|
99.26% |
| NP3-253 |
|
|
|
|
99.78% |
| NP3-562 |
|
|
|
|
98.16% |
| NP3-742 |
|
|
|
|
|
| NQO2 activator-1 |
|
|
|
|
|
| NT-0249 |
|
|
|
|
|
| NT-0249 free base |
|
|
|
|
95.17% |
| NT-0527 |
|
|
|
|
99.80% |
| NVP-DFV890 |
|
|
|
|
99.97% |
| ODZ10117 |
|
|
|
|
|
| Ofirnoflastum |
|
|
|
|
99.93% |
| Oxidized ATP trisodium salt |
|
|
|
|
98% |
| Oxidized low density lipoprotein (Human) |
|
|
|
|
|
| p-Ethoxychrysoidin |
|
|
|
|
|
| P2Y14 antagonist 1 |
|
|
|
|
|
| P2Y14R antagonist 1 |
|
|
|
|
98.76% |
| PDE/TRPA1/CHIT1-IN-1 |
|
|
|
|
|
| Peptide5 TFA |
|
|
|
|
98.87% |
| Phosphate muramyl dipeptide |
|
|
|
|
|
| Plantainoside D |
|
|
|
|
99.15% |
| PPARγ agonist-21 |
|
|
|
|
|
| PRDX1-IN-4 |
|
|
|
|
|
| PROTAC HDAC6 degrader 7 |
|
|
|
|
|
| QS-21-Api |
|
|
|
|
99.73% |
| RG100204 |
|
|
|
|
99.50% |
| RIPK2-IN-7 |
|
|
|
|
|
| RP-220 |
|
|
|
|
|
| Ruvonoflast |
|
|
|
|
99.29% |
| SBN-284 |
|
|
|
|
|
| Sebrinoflast |
|
|
|
|
|
| Selnoflast |
|
|
|
|
99.46% |
| Selnoflast calcium |
|
|
|
|
|
| Selnoflast monopotassium |
|
|
|
|
|
| Selnoflast potassium |
|
|
|
|
|
| SH-26 |
|
|
|
|
|
| SLC3037 |
|
|
|
|
99.85% |
| Soyasaponin II |
|
|
|
|
99.81% |
| Sweroside |
|
|
|
|
99.76% |
| Sweroside (Standard) |
|
|
|
|
98% |
| Teneligliptin hydrobromide |
|
|
|
|
99.99% |
| TLR7 agonist 27 |
|
|
|
|
|
| TN-101 |
|
|
|
|
|
| TN-783 |
|
|
|
|
|
| TriDAP |
|
|
|
|
|
| TriDAP dihydrochloride |
|
|
|
|
98.65% |
| URAT1-IN-16 |
|
|
|
|
|
| Usnoflast |
|
|
|
|
98.59% |
| VEN-02XX |
|
|
|
|
99.66% |
| XB2M54 |
|
|
|
|
|
| Xelafaslatide |
|
|
|
|
99.88% |
| Yadanzigan |
|
|
|
|
|
| YM-I-26 |
|
|
|
|
|
| YQ128 |
|
|
|
|
99.74% |
| ZM640 |
|
|
|
|
|
| ZM734 |
|
|
|
|
|
| α-Glucosidase/NLRP3-IN-1 |
|
|
|
|
|
| β-Aminoarteether |
|
|
|
|
99.29% |
| β-Aminoarteether maleate |
|
|
|
|
|
| Trimethylamine N-oxide |
|
|
|
|
98.0% |
| Trimethylamine N-oxide-d9 |
|
|
|
|
99.76% |
| Trimethylamine-N-oxide-13C3 |
|
|
|
|
|
| Dihydromethysticin |
|
|
|
|
99.71% |
| Trimethylamine N-oxide dihydrate |
|
|
|
|
99.86% |
| Echinatin |
|
|
|
|
99.83% |
| Pteryxin |
|
|
|
|
99.55% |
| (S)-(+)-Carvone |
|
|
|
|
99.26% |
| Stavudine |
|
|
|
|
99.89% |
| Stavudine-d4 |
|
|
|
|
|
| Stavudine sodium |
|
|
|
|
99.40% |
| Nigericin sodium salt |
|
|
|
|
99.60% |
| Nigericin |
|
|
|
|
99.64% |
| Isomangiferin |
|
|
|
|
99.60% |
| Tomaralimab |
|
|
|
|
99.42% |
| Ascorbyl palmitate |
|
|
|
|
99.62% |
| Dexpramipexole dihydrochloride |
|
|
|
|
99.94% |
| Dexpramipexole |
|
|
|
|
99.56% |
| Dexpramipexole-d3 dihydrochloride |
|
|
|
|
|
| Epimedin A |
|
|
|
|
99.43% |
| Periplogenin |
|
|
|
|
99.34% |
| Periplogenin (Standard) |
|
|
|
|
|
| Phaseoloidin |
|
|
|
|
99.92% |
| Aluminum Hydroxide |
|
|
|
|
97.0% |
| Teneligliptin hydrobromide hydrate |
|
|
|
|
99.97% |
| (+)-Magnoflorine chloride |
|
|
|
|
99.10% |
| Tabersonine |
|
|
|
|
98.02% |
| Tabersonine hydrochloride |
|
|
|
|
98.55% |
| Cyclo(Tyr-Phe) |
|
|
|
|
98.03% |
| Licochalcone B |
|
|
|
|
99.91% |
| 4'-Methoxyresveratrol |
|
|
|
|
99.48% |
| Drofenine hydrochloride |
|
|
|
|
98.0% |
| Articaine hydrochloride |
|
|
|
|
99.38% |
| Articaine hydrochloride (Standard) |
|
|
|
|
98% |
| Thiolutin |
|
|
|
|
99.27% |
| (+)-Magnoflorine iodide |
|
|
|
|
99.74% |
| Colchicine-d3 |
|
|
|
|
|
| Colchicine-d6 |
|
|
|
|
99.41% |
| Colchicine |
|
|
|
|
99.86% |
| Mifamurtide TFA |
|
|
|
|
98.0% |
| Mifamurtide |
|
|
|
|
99.58% |
| Mifamurtide sodium |
|
|
|
|
99.92% |
| Gypenoside XLIX |
|
|
|
|
99.88% |
| Troxerutin |
|
|
|
|
98.0% |
| 1,2,4-Trimethoxybenzene |
|
|
|
|
|
| Desmosterol |
|
|
|
|
99.40% |
| Dehydrodiisoeugenol |
|
|
|
|
99.98% |
| ATP |
|
|
|
|
99.88% |
| ATP-13C10,15N5,d14 (dilithium) |
|
|
|
|
|
| Suciraslimab |
|
|
|
|
97.42% |
| Nigakinone |
|
|
|
|
99.95% |
| Inclisiran |
|
|
|
|
98.96% |
| Inclisiran sodium |
|
|
|
|
99.08% |
| Caulerpin |
|
|
|
|
|
| Sipeimine |
|
|
|
|
98.57% |
| Physalin B |
|
|
|
|
97.20% |
| Alirocumab |
|
|
|
|
97.00% |
| Alirocumab (anti-PCSK9) |
|
|
|
|
98.01% |
| Apilimod hydrochloride |
|
|
|
|
|
| Arglabin |
|
|
|
|
99.87% |
| (-)-Maackiain |
|
|
|
|
99.50% |
| Ruscogenin |
|
|
|
|
99.85% |
| Muscone |
|
|
|
|
98.0% |
| Ergolide |
|
|
|
|
99.48% |
| Hecogenin acetate |
|
|
|
|
98.57% |